Characterization of the beta-lactam-resistant enzyme in Acanthamoeba castellanii.
Beta-lactams are well known as the best antibiotics for inhibiting the crosslink between the adjacent polysaccharide chains and peptides to cause bacterial cell lysis. There are no reports about the action and resistance mechanisms of beta-lactams in protozoa. Acanthamoeba castellanii is a free-living protozoan pathogen capable of causing blinding keratitis and fatal granulomatous encephalitis. When Acanthamoeba is exposed to harsh conditions, it differentiates into the cyst stage to avoid environmental stresses, such as drug treatment. In this study, we show that the mature encystation rate of Acanthamoeba castellanii is decreased by treatment with cefotaxime (CTX) and clavulanic acid (CLA); however, the drugs do not kill the amoeba. We hypothesize that β-lactam antibiotics may disturb double wall synthesis during the encystation process of Acanthamoeba. Interestingly, CTX is considered a powerful β-lactam; on the contrary, CLA is considered a weak β-lactam and an efficient β-lactamase inhibitor. We demonstrated that Acanthamoeba expresses β-lactamases to disturb the inhibition of the encystation process by β-lactams. To reveal the functions of Acanthamoeba β-lactamase, we produced a recombinant Acanthamoeba β-lactamase in Escherichia coli and showed resistance to β-lactams such as cefotaxime, cefuroxime, penicillin, and meropenem. Consequently, we suggest that Acanthamoeba produces enzymes similar to β-lactamase to avoid interference from the environment. In this study, we provide a new point of view on an important gene responsible for drug tolerance and advocate for the development of more efficient medicine against Acanthamoeba infection.